Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ertapenem Sodium

FDA-approved product (injectable, intramuscular, intravenous), marketed as Ertapenem Sodium, Invanz.

Registered studies
50+
Lab records
186
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ertapenem Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial pneumonia
  • Community-Acquired Infections
  • Gram-negative bacterial infections
  • Infection
  • Osteomyelitis
  • Staphylococcal skin infections
  • Streptococcal infection
  • Surgical Wound Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH03

Repurposing investigation

Ertapenem Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • K. pneumoniae99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 141 of 186 lab records
Open Ertapenem Sodium in ChEMBL Registered studies below
Show the latest 150 of 186 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ertapenem Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cefotetan Therapy for Escherichia Coli Infections

    NCT07318584 · start 2026-03

    Registered record
    Registry ID
    NCT07318584
    Conditions
    E Coli Infection; ESBL Producing E.Coli
    Interventions
    Cefotetan; Carbapenems; Beta Lactam Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionE Coli Infection; ESBL Producing E.Coli
    InterventionCefotetan; Carbapenems; Beta Lactam Antibiotics
    PhasePhase 2
    Registry statusNot yet recruiting

  • Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

    NCT07148960 · start 2025-09-15

    Registered record
    Registry ID
    NCT07148960
    Conditions
    Staphylococcus Aureus Bacteremia
    Interventions
    Early Dual IV Antibiotic Therapy - MRSA; Early Dual IV Antibiotic Therapy - MSSA; Single Agent IV Antibiotic Therapy - MRSA; Single Agent IV Antibiotic Therapy - MSSA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2025-09-15
    Completion
    2027-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia
    InterventionEarly Dual IV Antibiotic Therapy - MRSA; Early Dual IV Antibiotic Therapy - MSSA; Single Agent IV Antibiotic Therapy - MRSA; Single Agent IV Antibiotic Therapy - MSSA
    PhasePhase 4
    Registry statusEnrolling by invitation

  • Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

    NCT04886284 · start 2024-05-20

    Registered record
    Registry ID
    NCT04886284
    Conditions
    Staphylococcus Aureus Bacteremia; Staphylococcus Aureus Septicemia; Staphylococcal Sepsis; Staphylococcus Aureus Endocarditis
    Interventions
    Ertapenem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-05-20
    Completion
    2027-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Bacteremia; Staphylococcus Aureus Septicemia; Staphylococcal Sepsis; Staphylococcus Aureus Endocarditis
    InterventionErtapenem; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Antimicrobial Resistance in Hospitals From Meta, Colombia

    NCT06044272 · start 2023-09-01

    Registered record
    Registry ID
    NCT06044272
    Conditions
    Increased Drug Resistance
    Interventions
    Factors associated
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-09-01
    Completion
    2024-06-30
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIncreased Drug Resistance
    InterventionFactors associated
    PhaseNot recorded
    Registry statusCompleted

  • BALANCE+ Vanguard Phase

    NCT05893147 · start 2023-08-26

    Registered record
    Registry ID
    NCT05893147
    Conditions
    Gram-negative Bacteremia
    Interventions
    De-escalation VS No De-escalation; Oral beta-lactams VS non beta-lactams; Central vascular catheter retention VS Central vascular catheter replacement; Cephalosporin VS Carbapenem for low risk AmpC organisms; Routine follow-up blood culture VS No routine follow-up blood culture
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-08-26
    Completion
    2024-08-10
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-negative Bacteremia
    InterventionDe-escalation VS No De-escalation; Oral beta-lactams VS non beta-lactams; Central vascular catheter retention VS Central vascular catheter replacement; Cephalosporin VS Carbapenem for low risk AmpC organisms +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs

    NCT05224401 · start 2023-05-29

    Registered record
    Registry ID
    NCT05224401
    Conditions
    Urinary Tract Infections; Bacteremia; Antibiotic Resistant Infection
    Interventions
    Pivmecillinam and amoxicillin/clavulanic acid; Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-05-29
    Completion
    2027-09-01
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Bacteremia; Antibiotic Resistant Infection
    InterventionPivmecillinam and amoxicillin/clavulanic acid; Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibility
    PhasePhase 3
    Registry statusRecruiting

  • Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)

    NCT05645757 · start 2023-04-19

    Registered record
    Registry ID
    NCT05645757
    Conditions
    Bacterial Infection
    Interventions
    Ertapenem; Placebo; WCK 6777; Zidebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-04-19
    Completion
    2023-11-03
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection
    InterventionErtapenem; Placebo; WCK 6777; Zidebactam
    PhasePhase 1
    Registry statusCompleted

  • Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center

    NCT06739382 · start 2021-01-01

    Registered record
    Registry ID
    NCT06739382
    Conditions
    Ventilation Acquired Pneumonia
    Interventions
    extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin.; two β-lactam antibiotics plus a single non-β-lactam antibiotic; Control group received standard therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-01-01
    Completion
    2022-01-01
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilation Acquired Pneumonia
    Interventionextended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin.; two β-lactam antibiotics plus a single non-β-lactam antibiotic; Control group received standard therapy
    PhasePhase 3
    Registry statusCompleted

  • Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients

    NCT04748120 · start 2020-12-28

    Registered record
    Registry ID
    NCT04748120
    Conditions
    Covid19; Appendicitis; Cholecystitis, Acute; Cholecystitis; Gallstone; Cholecystitis
    Interventions
    Operative management; Non-operative management
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2020-12-28
    Completion
    2021-04-06
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; Appendicitis; Cholecystitis, Acute; Cholecystitis +2 more
    InterventionOperative management; Non-operative management
    PhaseNot applicable
    Registry statusTerminated

  • Comparison of Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella Pneumoniae

    NCT04229498 · start 2020-04

    Registered record
    Registry ID
    NCT04229498
    Conditions
    Bloodstream Infection
    Interventions
    Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-04
    Completion
    2021-11
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBloodstream Infection
    InterventionMonotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
    PhaseNot recorded
    Registry statusUnknown

  • Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia

    NCT03925402 · start 2019-05-15

    Registered record
    Registry ID
    NCT03925402
    Conditions
    Bacteremia; Infection, Bacterial
    Interventions
    Ertapenem; Carbapenems
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-15
    Completion
    2022-10-01
    Enrolment
    427

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia; Infection, Bacterial
    InterventionErtapenem; Carbapenems
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

    NCT04505683 · start 2018-12-13

    Registered record
    Registry ID
    NCT04505683
    Conditions
    Complicated Urinary Tract Infection Including Acute Pyelonephritis
    Interventions
    Benapenem; Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2018-12-13
    Completion
    2020-05-08
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection Including Acute Pyelonephritis
    InterventionBenapenem; Ertapenem
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas

    NCT03582007 · start 2018-10-22

    Registered record
    Registry ID
    NCT03582007
    Conditions
    Pneumonia
    Interventions
    Murepavadin; One anti-pseudomonal antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-10-22
    Completion
    2019-07-17
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionMurepavadin; One anti-pseudomonal antibiotic
    PhasePhase 3
    Registry statusTerminated

  • Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

    NCT03358576 · start 2018-09-18

    Registered record
    Registry ID
    NCT03358576
    Conditions
    Intra Abdominal Infections
    Interventions
    Ertapenem; Sulopenem-Etzadroxil/Probenecid; Ciprofloxacin; Metronidazole; Amoxicillin-Clavulanate; Sulopenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-18
    Completion
    2019-10-02
    Enrolment
    674

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntra Abdominal Infections
    InterventionErtapenem; Sulopenem-Etzadroxil/Probenecid; Ciprofloxacin; Metronidazole +2 more
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis

    NCT05896930 · start 2017-11-09

    Registered record
    Registry ID
    NCT05896930
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Meropenem 6g IV over 6 hours; Ertapenem 1g IM; Meropenem 3g IV; Ertapenem 1g IV; Amoxicillin/CA twice daily; Rifampicin 35 mg/kg; Meropenem 6g IV over 60 minutes; Rifafour e-275; Meropenem 4g IV; Amoxicillin/CA once daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-11-09
    Completion
    2021-01-04
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionMeropenem 6g IV over 6 hours; Ertapenem 1g IM; Meropenem 3g IV; Ertapenem 1g IV +6 more
    PhasePhase 2
    Registry statusCompleted